Gilead SciencesFRA:GIS +0.55%75 Dividend Yield % is 2.50% as of Jun. 25, 2026, which is 28% below its 10-year median of 3.48. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €82.28 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 516 Drug Manufacturers companies, Gilead Sciences ranks better than 59.11% on this metric.
As of today (2026-06-25), the Trailing Annual Dividend Yield of Gilead Sciences is 2.50%.
The historical rank and industry rank for Gilead Sciences's Dividend Yield % or its related term are showing as below:
FRA:GIS'
s Dividend Yield % Range Over the Past 10 Years
Min: 2.03 Med: 3.48 Max: 4.9
Current: 2.5
During the past 13 years, the highest Dividend Yield of Gilead Sciences was 4.90%. The lowest was 2.03%. And the median was 3.48%.
FRA:GIS's Dividend Yield % is ranked better than 59.11% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.005
vs FRA:GIS: 2.50
During the past 12 months, Gilead Sciences's average Dividends Per Share Growth Rate was 2.90% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 2.70% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 3.00% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 7.80% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Gilead Sciences was 20.90% per year. The lowest was 2.70% per year. And the median was 6.30% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Gilead Sciences's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GIS vs AMGN, PFE, BMY: Dividend Yield % Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Gilead Sciences Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 0.820000
2026-06-15
2026-06-15
2026-06-29
Cash Dividend
quarterly
USD:EUR 0.856000
USD 0.820000
2026-03-13
2026-03-13
2026-03-30
Cash Dividend
quarterly
USD:EUR 0.865000
USD 0.790000
2025-12-15
2025-12-15
2025-12-30
Cash Dividend
quarterly
USD:EUR 0.854000
USD 0.790000
2025-09-15
2025-09-15
2025-09-29
Cash Dividend
quarterly
USD:EUR 0.852000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Gilead Sciences's Trailing Annual Dividend Yield (%) for Today is calculated as
Gilead Sciences's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
2.80768
/
109.12
=
2.57 %
Current Share Price is €109.12. Gilead Sciences's Dividends per Share for the forward twelve months is calculated as €0.70192 * 4 = €2.80768.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a Dividend Yield % of 2.50% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Gilead Sciences and its competitors. This is 28% below median its historical median of 3.48. Over the past decade, Gilead Sciences' Dividend Yield % has ranged from 2.03 to 4.90. According to the industry distribution chart, Gilead Sciences ranks #211 out of 516 companies in the Drug Manufacturers industry, placing it in the top 40.9%.
Is Gilead Sciences' Dividend Yield % too high?
Gilead Sciences' current Dividend Yield % of 2.50% is 28% below median its 10-year median of 3.48. Over the past 10 years, this metric has ranged from a low of 2.03 to a high of 4.90. The Drug Manufacturers industry median Dividend Yield % is 2.01. Gilead Sciences' value of 2.50% is 24.7% above this industry median. Based on the distribution chart, Gilead Sciences ranks #211 out of 516 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Dividend Yield % compare to AMGN and PFE?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #211 out of 516 companies for Dividend Yield %. This puts Gilead Sciences in the upper half of its industry. The industry median Dividend Yield % is 2.01. Gilead Sciences' value of 2.50% is 24.7% above this benchmark. Historically, Gilead Sciences' own Dividend Yield % has ranged from 2.03 to 4.90 over the past decade. While the company's 10-year median is 3.48 vs. the industry median of 2.01, Gilead Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.01, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current Dividend Yield % of 2.50% is 24.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current Dividend Yield % is 2.50%, which is 28% below median its own 10-year median of 3.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.28, compared to a current price of €109.12 — trading 32.6% above its estimated fair value. The current Dividend Yield % is 2.50%, which is 28% below median its 10-year median of 3.48 and 24.7% above the Drug Manufacturers industry median of 2.01. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Dividend Yield % is 2.50% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €109.12 is trading 32.6% above its estimated GF Value™ of €82.28.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
Dividend Yield %: 2.50% (28% below median its 10-year median of 3.48)
GF Value™: €82.28 vs. price of €109.12 (32.6% above fair value)
Industry Position: 24.7% above the Drug Manufacturers median (#211 of 516)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score
Get the complete analysis for FRA:GIS
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
